( x* \; }/ ~. Y+ |
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:" I# h9 b. q$ G/ W1 X
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. $ M' U" g; m/ ^9 ]/ n, F5 M. ]http://www.ncbi.nlm.nih.gov/pubmed/229681848 ]: x+ f% L$ l4 m3 C